Tirzepatide demonstrated approximately 5-fold lower affinity at the GLP-1 receptor compared to native GLP-1, and 20-fold lower potency in cellular signaling compared to semaglutide
This may be due to its anti-inflammatory, antimicrobial, and immune-boosting properties
PPAR- is also highly expressed in adipose tissue where it controls adipocyte differentiation and plays a crucial role in increasing insulin sensitivity and promoting fatty acid uptake into adipocytes.[88], [89] The phase IIb trial of elafibranor, GOLDEN-505, was an international, randomised, placebo-controlled trial of 276 patients with biopsy proven NASH in the absence of cirrhosis, with a primary outcome of resolution of NASH defined by disappearance of steatosis, ballooning or lobular inflammation
In the obesity trials, participants on the 12 mg dose reached up to roughly 2829% mean body-weight reduction at 68 to 80 weeks, with a large share crossing the 25% and 30% thresholds, the strongest weight result reported for a GLP-1-class compound in a phase 3 trial [5]
The key advantage of compounding is flexibility and affordability
One of the tools we offer is Semaglutide GLP-1, a medication that can be a valuable part of your weight loss strategy
